References
1. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy - Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest . 2012;141:e44S-e88S.
2. Ufer M. Comparative Pharmacokinetics of Vitamin K Antagonists.Clin Pharmacokinet . 2005;44:1227-1246.
3. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med . 2005;165:1095-1106.
4. Beinema M, Brouwers JRBJ, Schalekamp T, Wilffert B. Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.Thromb Haemost . 2008;100:1052-1057.
5. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ . 2014;349:1-10.
6. Sirtori CR. The pharmacology of statins. Pharmacol Res . 2014;88:3-11.
7. Hellfritzsch M, Lund LC, Ennis Z, et al. Ischemic Stroke and Systemic Embolism in Warfarin Users With Atrial Fibrillation or Heart Valve Replacement Exposed to Dicloxacillin or Flucloxacillin. Clin Pharmacol Ther . 2020;107:607-616.
8. Lexicomp® Drug Interactions - UpToDate.
9. Drug Interactions search - MICROMEDEX.
10. Interaktionsdatabasen.dk.
11. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement.Rev Esp Nutr Humana y Diet . 2016;20:148-160.
12. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: Elaboration and explanation. BMJ . 2015;350:1-25.
13. Andersson ML, Mannheimer B, Lindh JD. The effect of simvastatin on warfarin anticoagulation: a Swedish register-based nationwide cohort study. Eur J Clin Pharmacol . 2019;75:1387-1392.
14. Kamali F, Hickmott H, Wynne H. The effect of simvastatin co-medication on warfarin anticoagulation response and dose requirements. Thromb Haemost . 2003;89:949-950.
15. Simonson SG, Martin PD, Mitchell PD, Lasseter K, Gibson G, Schneck DW. Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics. J Clin Pharmacol . 2005;45:927-934.
16. Stern R, Abel R, Gibson GL BJ. Atorvastatin Does Not Alter the Anticoagulant Activity of Warfarin. J Clin Pharmacol . 1997;37:1062-1064.
17. van Rein N, Biedermann JS, Bonafacio SM, Kruip MJHA, van der Meer FJM, Lijfering WM. Statin use decreases coagulation in users of vitamin K antagonists. Eur J Clin Pharmacol . 2016;72:1441-1447.
18. Schelleman H, Bilker WB, Brensinger CM, Wan F, Yang YX, Hennessy S. Fibrate/Statin Initiation in Warfarin Users and Gastrointestinal Bleeding Risk. Am J Med . 2010;123:151-157.
19. Engell AE, Svendsen ALO, Lind BS, et al. Drug‐drug interaction between warfarin and statins: A Danish cohort study. Br J Clin Pharmacol . Published online 2020:1-6.
20. Hansen PW, Clemmensen L, Sehested TSG, et al. Identifying Drug-Drug Interactions by Data Mining: A Pilot Study of Warfarin-Associated Drug Interactions. Circ Cardiovasc Qual Outcomes . 2016;9:621-628.
21. Sun Q, Welsh KJ, Bruns DE, Sacks DB, Zhao Z. Inadequate reporting of analytical characteristics of biomarkers used in clinical research: A threat to interpretation and replication of study findings. Clin Chem . 2019;65:1554-1562.
22. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clinical relevance.Clin Pharmacokinet . 2000;38:111-180.
23. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month.Circulation . 1997;95:1126–1131.
24. Wiklund O, Pirazzi C, Romeo S. Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. Curr Cardiol Rep . 2013;15:397.